Hormonal
Tirzepatide use is associated with a very low absolute risk of acute pancreatitis (<1%), and when cases occur, they are typically mild and confounded by traditional etiologies such as gallstones or alcohol.
If you are taking tirzepatide, be aware that pancreatitis is a known but rare side effect (<1% risk). Most cases are mild and often linked to other factors like gallstones. Report severe abdominal pain to your doctor immediately, but do not let fear of this rare event prevent you from using a medication that effectively manages weight and blood sugar.
In this single-centre audit, pancreatitis in patients receiving tirzepatide was rare, mild, and commonly associated with other aetiologies, such as gallstones or alcohol. ... the overall risk appears low.
Why this rating
Single-center retrospective audit with a very small exposed cohort (n=4), limiting statistical power and generalizability, though aligned with larger meta-analyses.
Source
Pancreatitis in Patients Receiving Tirzepatide (Mounjaro): A One-Year Audit in a UK District General Hospital
Asmita Hossain et al. · Cureus · 2025
DOI 10.7759/cureus.96974
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →